High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center

Samuel L. Aitken, Jeffrey J. Tarrand, Lalitagauri M. Deshpande, Frank P. Tverdek, Anne L. Jones, Samuel A. Shelburne, Randall A. Prince, Micah M. Bhatti, Kenneth V.I. Rolston, Ronald N. Jones, Mariana Castanheira, Roy F. Chemaly

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.

Original languageEnglish (US)
Pages (from-to)954-958
Number of pages5
JournalClinical Infectious Diseases
Volume63
Issue number7
DOIs
StatePublished - Oct 1 2016

Keywords

  • CRE
  • NDM
  • bacteremia
  • carbapenemase
  • ceftazidime-avibactam

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center'. Together they form a unique fingerprint.

Cite this